Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Recommendation of "Buy" from Analysts

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) has received an average recommendation of "Buy" from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.00.

CLBT has been the subject of a number of research reports. Lake Street Capital upped their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently added to or reduced their stakes in CLBT. Assetmark Inc. bought a new position in shares of Cellebrite DI during the first quarter valued at about $33,000. Catalyst Capital Advisors LLC purchased a new position in Cellebrite DI during the 1st quarter valued at about $51,000. Gen Wealth Partners Inc bought a new position in Cellebrite DI during the 4th quarter valued at approximately $85,000. NewEdge Advisors LLC lifted its holdings in Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after buying an additional 3,352 shares during the period. Finally, R Squared Ltd purchased a new stake in Cellebrite DI in the 4th quarter worth approximately $100,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

CLBT traded up $0.27 on Monday, reaching $20.12. The company had a trading volume of 1,197,743 shares, compared to its average volume of 1,431,747. Cellebrite DI has a 52-week low of $10.25 and a 52-week high of $26.30. The company has a market cap of $4.82 billion, a price-to-earnings ratio of -14.47, a P/E/G ratio of 4.27 and a beta of 1.44. The business has a 50 day simple moving average of $18.95 and a 200 day simple moving average of $20.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities research analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.